BORDETELLA PERTUSSIS TOXIN (FROZEN)

Bordetella pertussis toxin (frozen) has been developed in response to the increasing pressure on the IVD industry to supply highly specific, cost-effective antibody capture systems, which are needed for monitoring vaccination programmes. The toxin undergoes two rounds of FHA (Filamentous Haemagglutinin) removal and manufacturing procedures are geared to ensure minimal lot to lot variation. Liquid presentation is the optimal presentation for minimising aggregation, for providing bulk lots to IVD, and for ease of aliquoting, freeze/thawing and storage.